Literature DB >> 15965925

Genotype-phenotype relationships in hepatocellular tumors from mice and man.

Sabine Stahl1, Carina Ittrich, Philip Marx-Stoelting, Christoph Köhle, Ozge Altug-Teber, Olaf Riess, Michael Bonin, Jürgen Jobst, Stephan Kaiser, Albrecht Buchmann, Michael Schwarz.   

Abstract

Experimentally induced liver tumors in mice harbor activating mutations in either Catnb (beta-catenin) or Ha-ras, according to the carcinogenic treatment. We have now investigated by microarray analysis the gene expression profiles in tumors of the two genotypes. In total, 364 genes or expressed sequences with aberrant expression relative to normal liver were identified, but only 30 of these demonstrated unidirectional changes in both tumor types. Several functional clusters were identified that involve changes in amino acid utilization and ammonia disposition in Catnb-mutated tumors as opposed to alterations in lipid and cholesterol metabolism in Ha-ras-mutated tumors. Moreover, several genes coding for inhibitory molecules within the Wnt-signaling pathway were upregulated in Catnb-mutated tumors, suggesting induction of a negative feedback loop, whereas Ha-ras-mutated tumors showed alterations in the expression of several genes functional in monomeric G-protein signaling. We conclude that mouse hepatoma cells adopt different evolutionary strategies that allow for their selective outgrowth under variable environmental conditions. Human hepatocellular cancers (HCC) lack RAS mutations but are frequently mutated in CTNNB1, the human Catnb ortholog. The set of genes aberrantly expressed in Catnb-mutated mouse tumors was used to screen, by expression profiling, for dysregulation of orthologous genes within a panel of 25 HCCs, of which 10 were CTNNB1-mutated. HCCs with activated beta-catenin displayed a gene expression profile that was similar to Catnb-mutated mouse tumors but distinct from the other human HCCs. In conclusion, expression fingerprints may be used for diagnostic purposes and potential new therapeutic intervention strategies. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index/html).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965925     DOI: 10.1002/hep.20768

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Effect of mutant β-catenin on liver growth homeostasis and hepatocarcinogenesis in transgenic mice.

Authors:  Timothy J Stein; Adam Jochem; Katie E Holmes; Eric P Sandgren
Journal:  Liver Int       Date:  2011-01-19       Impact factor: 5.828

Review 2.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

3.  Alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis in male mice through activation of the Wnt/β-catenin signaling pathway.

Authors:  Kelly E Mercer; Leah Hennings; Neha Sharma; Keith Lai; Mario A Cleves; Rebecca A Wynne; Thomas M Badger; Martin J J Ronis
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-28

Review 4.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

5.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

6.  Comparative analysis of proteome and transcriptome in human hepatocellular carcinoma using 2D-DIGE and SAGE.

Authors:  Hirotaka Minagawa; Taro Yamashita; Masao Honda; Yo Tabuse; Kenichi Kamijo; Akira Tsugita; Shuichi Kaneko
Journal:  Protein J       Date:  2008-12       Impact factor: 2.371

Review 7.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

8.  TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.

Authors:  Jiayi Wang; Joo-Seop Park; Yingying Wei; Mihir Rajurkar; Jennifer L Cotton; Qishi Fan; Brian C Lewis; Hongkai Ji; Junhao Mao
Journal:  Mol Cell       Date:  2013-06-13       Impact factor: 17.970

9.  Cytokeratin 7/19 expression in N-diethylnitrosamine-induced mouse hepatocellular lesions: implications for histogenesis.

Authors:  Nuno P Santos; Paula A Oliveira; Regina Arantes-Rodrigues; Ana I Faustino-Rocha; Aura Colaço; Carlos Lopes; Rui M Gil da Costa
Journal:  Int J Exp Pathol       Date:  2014-04-15       Impact factor: 1.925

10.  Hepatocellular carcinomas in B6C3F1 mice treated with Ginkgo biloba extract for two years differ from spontaneous liver tumors in cancer gene mutations and genomic pathways.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Snyder; Hue-Hua L Hong; Thai-Vu Ton; Shyamal Peddada; Keith Shockley; Kristine Witt; Po Chan; Cynthia Rider; Linda Kooistra; Abraham Nyska; Robert C Sills
Journal:  Toxicol Pathol       Date:  2012-12-21       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.